Skip to content
Find a Provider
Patrick M. Reagan, M.D.

Patrick M. Reagan, M.D.

Hematology & Oncology , Cancer

5 out of 5 stars
323 Ratings
37 Comments
UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

Appointment (585) 275-5823
Fax (585) 784-7097

Locations

Wilmot Cancer Center - Rochester

Strong Memorial Hospital
90 Crittenden Boulevard
Rochester, NY 14642

(585) 275-5830 Get Directions

About Me

I am a clinician and researcher specializing in the care of patients with both Non Hodgkin and Hodgkin lymphomas. Areas of particular interest include aggressive B-cell lymphomas, autologous stem cell transplantation and cellular therapy including chimeric antigen receptor (CAR) T-cells.

Lym...
I am a clinician and researcher specializing in the care of patients with both Non Hodgkin and Hodgkin lymphomas. Areas of particular interest include aggressive B-cell lymphomas, autologous stem cell transplantation and cellular therapy including chimeric antigen receptor (CAR) T-cells.

Lymphomas are a complex group of diseases and require a multidisciplinary team to manage. We are fortunate to have an excellent team at the Wilmot Cancer Institute including hematology and oncology, radiation oncology, hematopathology, dermatology, neurology, nursing, advanced practice providers, social work and members of the clinical trials office.

I am actively engaged in clinical trials research and feel that this is an important component of care for lymphoma patients.

Certified Specialties

Hematology - American Board of Internal Medicine

Faculty Appointments

Associate Professor - Department of Medicine, Hematology/Oncology (SMD)

Credentials

Residency & Fellowship

Fellowship, Hematology & Oncology, University of Rochester Medical Center. 2013 - 2015

Residency, Internal Medicine, University of Virginia-Radiology GME. 2012 - 2013

Residency, Internal Medicine, University of Virginia-Radiology GME. 2010 - 2012

Internship, Internal Medicine, University of Virginia-Radiology GME. 2009 - 2010

Education

MD | SUNY Upstate College of Health Professions. 2009

Awards

Wilmot Cancer Institute Inspiration Award Immune Effector Cell Therapy Team. 2022

Lymphoma Research Foundation Clinical Research Mentoring Program. 2018

American Society of Hematology Clinical Research Training Institute. 2015

John and Carol Bennett Travel Fellowship Award. 2014

Alpha Omega Alpha, Upstate Medical University. 2009

Phi Beta Kappa, St. Lawrence University. 2005

Academic All American, Football, St. Lawrence University. 2004

Beta Beta Beta, Biological Honor Society, St. Lawrence University.

Research

Clinical Trials

A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma

Lead Researcher: Patrick M Reagan

The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-23)

Lead Researcher: Patrick M Reagan

The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.

A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma

Lead Researcher: Patrick M Reagan

This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabta...

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Lead Researcher: Patrick M Reagan

The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in particip...

Phase 2 Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

Lead Researcher: Patrick M Reagan

The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.

Publications

Journal Articles

Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL.

Khurana A, Mwangi R, Nastoupil LJ, Reagan PM, Farooq U, Romancik JT, McDonnell T, Riska S, Lossos IS, Kahl BS, Martin P, Witzig TE, Cerhan JR, Flowers CR, Nowakowski GS, Maurer MJ

Blood advances.. 2024 August 278 (16):4414-4422. Epub 1900 01 01.

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

Jain MD, Spiegel JY, Nastoupil LJ, Tamaresis J, Ghobadi A, Lin Y, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Dorritie KA, Sehgal AR, Goy A, Hill BT, Andreadis C, Munoz J, Ulrickson M, Westin J, Chavez JC, Patel D, Jacobs MT, Bansal R, Bennani NN, Patel VG, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL, Lunning M, Dahiya S

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2024 August 2 :JCO2302786. Epub 08/02/2024.

Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7.

Ghobadi A, Munoz J, Westin JR, Locke FL, Miklos DB, Rapoport AP, Perales MA, Reagan PM, McGuirk JP, Jacobson CA, Kersten MJ, Avivi I, Peng A, Schupp M, To C, Oluwole OO

Blood advances.. 2024 June 118 (11):2982-2990. Epub 1900 01 01.

Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium.

Jain MD, Jacobs MT, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning MA, Lekakis LJ, Reagan PM, Oluwole OO, McGuirk JP, Deol A, Sehgal A, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL, Ghobadi A

Blood advances.. 2024 February 278 (4):1042-1050. Epub 1900 01 01.

Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment.

Roschewski M, Patel MR, Reagan PM, Saba NS, Collins GP, Arkenau HT, de Vos S, Nuttall B, Acar M, Burke K, White RD, Udriste M, Sharma S, Dougherty B, Stetson D, Jenkins D, Mortlock A, Forcina A, Munugalavadla V, Flinn I

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2023 September 129 (17):3301-3312. Epub 1900 01 01.

Healthcare Utilization Disparities of Adolescent and Young Adults Compared to the Older Lymphoma Population.

Thapa K, Strawderman M, Reagan PM, Barr PM, Zent CS, Friedberg JW, Faugh T, Casulo C

Clinical lymphoma, myeloma & leukemia.. 2023 September 23 (9):e260-e267. Epub 05/23/2023.

Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.

Wallace DS, Rowland C, Hill BT, Baran AM, Casulo C, Reagan PM, Winter A, Karmali R, Winter JN, Gordon LI, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Ma S, Barr PM

Leukemia & lymphoma.. 2023 September 64 (9):1579-1582. Epub 06/21/2023.

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.

Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, Rapoport AP, Sureda A, Jacobson CA, Farooq U, van Meerten T, Ulrickson M, Elsawy M, Leslie LA, Chaganti S, Dickinson M, Dorritie K, Reagan PM, McGuirk J, Song KW, Riedell PA, Minnema MC, Yang Y, Vardhanabhuti S, Filosto S, Cheng P, Shahani SA, Schupp M, To C, Locke FL,

The New England journal of medicine.. 2023 July 13389 (2):148-157. Epub 06/05/2023.

Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia.

Wallace DS, Zent CS, Baran AM, Reagan PM, Casulo C, Rice G, Friedberg JW, Barr PM

Blood advances.. 2023 June 137 (11):2496-2503. Epub 1900 01 01.

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.

Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2023 January 2041 (3):555-567. Epub 06/04/2022.

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.

Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, Tomas AA, Sauter C, Perales MA, Shah NN, Acharya UH, Jacobson C, Soiffer RJ, Wang T, Komanduri KV, Jaglowski S, Kittai AS, Denlinger N, Iqbal M, Kharfan-Dabaja MA, Ayala E, Chavez J, Jain M, Locke FL, Samara Y, Budde LE, Mei MG, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, Hamadani M, Herrera AF

Haematologica.. 2023 January 1108 (1):98-109. Epub 01/01/2023.

PD-1 CAR-T cells provide superior protection against solid tumors.

Sailer CJ, Hong Y, Dahal A, Ryan AT, Mir S, Gerber SA, Reagan PM, Kim M

Frontiers in immunology.. 2023 14 :1187850. Epub 06/14/2023.

Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium.

Jacobs MT, Jain MD, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan PM, Oluwole OO, McGuirk J, Deol A, Sehgal A, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Ghobadi A, Locke FL

Clinical lymphoma, myeloma & leukemia.. 2022 October 22 (10):753-759. Epub 05/23/2022.

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.

Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, Nath R, Solomon SR, Champion R, Licitra E, Fanning S, Gupta N, Dubowy R, D'Andrea A, Wang L, Ogasawara K, Thorpe J, Gordon LI

The Lancet. Oncology.. 2022 August 23 (8):1066-1077. Epub 07/12/2022.

Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey.

Harkins RA, Patel S, Lee MJ, Switchenko JM, Ansell SM, Bartlett NL, Blum K, Cashen AF, Casulo C, Friedberg JW, Johnston P, Kahl BS, Leonard JP, Link BK, Lossos IS, Martin P, Maurer MJ, Mehta-Shah N, Reagan P, Westin JR, Koff JL, Flowers CR

Blood advances.. 2022 May 106 (9):2745-2756. Epub 1900 01 01.

Cytopenia after CAR-T Cell Therapy-A Brief Review of a Complex Problem.

Sharma N, Reagan PM, Liesveld JL

Cancers.. 2022 March 1514 (6)Epub 03/15/2022.

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.

Shadman M, Pasquini MC, Ahn KW, Chen Y, Turtle CJ, Hematti P, Cohen JB, Khimani F, Ganguly S, Merryman RW, Yared JA, Locke FL, Ahmed N, Munshi P, Beitinjaneh A, Reagan P, Herrera AF, Sauter CS, Kharfan-Dabaja MA, Hamadani M

Blood.. 2022 March 3139 (9):1330-1339. Epub 1900 01 01.

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR,

The New England journal of medicine.. 2022 February 17386 (7):640-654. Epub 12/11/2021.

Longitudinal Changes in Cognitive Function in a Nationwide Cohort Study of Patients With Lymphoma Treated With Chemotherapy.

Janelsins MC, Mohamed M, Peppone LJ, Magnuson A, Belcher EK, Melnik M, Dakhil S, Geer J, Kamen C, Minasian L, Reagan PM, Mohile SG, Morrow GR, Ahles TA, Heckler CE

Journal of the National Cancer Institute.. 2022 January 11114 (1):47-59. Epub 1900 01 01.

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan P, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Crump M, Kuruvilla J, Van Den Neste EW, Farooq U, Navale L, DePuy V, Kim JJ, Gisselbrecht C

Blood advances.. 2021 October 265 (20):4149-4155. Epub 1900 01 01.

Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy.

Spiegel JY, Dahiya S, Jain MD, Tamaresis JS, Nastoupil L, Jacobs MT, Ghobadi A, Lin Y, Lunning M, Lekakis LJ, Reagan P, Oluwole OO, McGuirk JP, Deol A, Goy A, Vu K, Andreadis C, Munoz J, Bennani NN, Vose J, Dorritie KA, Neelapu SS, Locke FL, Rapoport AP, Hill B, Miklos DB

Blood.. 2021 April 1137 (13):1832-1835. Epub 1900 01 01.

Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.

Reagan PM, Friedberg JW

Future oncology.. 2021 April 17 (11):1269-1283. Epub 01/15/2021.

Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells.

Wallace D, Reagan PM

Drugs.. 2021 April 81 (6):669-684. Epub 03/30/2021.

Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma.

Rodgers TD, Williams AM, Baran A, Reagan PM, Casulo C, Zent CS, Evans A, Friedberg JW, Barr PM

Leukemia & lymphoma.. 2021 March 62 (3):598-605. Epub 10/25/2020.

How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies.

Reagan PM, Neelapu SS

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2021 February 1039 (5):456-466. Epub 01/12/2021.

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.

Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, Oluwole OO, Reagan PM, Lekakis LJ, Lin Y, Sherman M, Better M, Go WY, Wiezorek JS, Xue A, Bot A

Blood advances.. 2020 October 134 (19):4898-4911. Epub 1900 01 01.

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2020 September 2038 (27):3119-3128. Epub 05/13/2020.

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM

The New England journal of medicine.. 2020 April 2382 (14):1331-1342. Epub 1900 01 01.

Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma.

Rodgers TD, Baran A, Reagan PM, Casulo C, Zent C, Evans A, Burack R, Williams AM, Friedberg JW, Barr PM

British journal of haematology.. 2020 February 188 (4):e33-e36. Epub 12/17/2019.

Advancing age and the risk of bleomycin pulmonary toxicity in a largely older cohort of patients with newly diagnosed Hodgkin Lymphoma.

Thomas TS, Luo S, Reagan PM, Keller JW, Sanfilippo KM, Carson KR

Journal of geriatric oncology.. 2020 January 11 (1):69-74. Epub 10/24/2019.

Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation.

Loh KP, Baran A, Lee CY, Alshaibani A, Rutherford SC, Hu J, Casulo C, Barr PM, Friedberg JW, Reagan PM

Leukemia & lymphoma.. 2019 December 60 (14):3569-3572. Epub 07/08/2019.

Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib.

Tomlinson SB, Sandwell S, Chuang ST, Johnson MD, Vates GE, Reagan PM

Leukemia research.. 2019 August 83 :106164. Epub 05/28/2019.

Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience.

Williams AM, Baran AM, Casulo C, Reagan P, Friedberg JW, Helber M, Moore J, Baloga E, Zent CS, Barr PM

Clinical lymphoma, myeloma & leukemia.. 2019 January 19 (1):41-47. Epub 10/13/2018.

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS

The Lancet. Oncology.. 2019 January 20 (1):31-42. Epub 12/02/2018.

Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.

David RJ, Baran A, Loh KP, Casulo C, Barr PM, Friedberg JW, Reagan PM

Clinical lymphoma, myeloma & leukemia.. 2018 December 18 (12):781-787. Epub 08/29/2018.

Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.

Frank MJ, Reagan PM, Bartlett NL, Gordon LI, Friedberg JW, Czerwinski DK, Long SR, Hoppe RT, Janssen RS, Candia AF, Coffman RL, Levy R

Cancer discovery.. 2018 October 8 (10):1258-1269. Epub 08/28/2018.

Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.

Rodgers TD, Reagan PM

Expert opinion on emerging drugs.. 2018 June 23 (2):111-122. Epub 06/06/2018.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY

The New England journal of medicine.. 2017 December 28377 (26):2531-2544. Epub 12/10/2017.

Current treatment of double hit and double expressor lymphoma.

Reagan PM, Davies A

Hematology. 2017 December 82017 (1):295-297. Epub 1900 01 01.

Reassessment of Anti-CD20 Therapy in Lymphoid Malignancies: Impact, Limitations, and New Directions.

Reagan PM, Friedberg JW

Oncology.. 2017 May 1531 (5):402-11. Epub 1900 01 01.

Chemotherapy-free treatment in non-Hodgkin lymphoma: a steep learning curve.

Reagan PM, Barr PM

The Lancet. Haematology.. 2017 April 4 (4):e152-e153. Epub 03/15/2017.

Poor survival with high-dose chemotherapy and autologous stem cell support in double-hit and double-expressor B-cell lymphomas. Translational Cancer Research, 2017. 6: p. S249-S253.

Reagan, P.M. and J.W. Friedberg.

Translational Cancer Research,. 2017; 6: S249-S253.

Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma.

Reagan PM, Baran A, Kelly JL, Barr PM, Casulo C, Chengazi VU, Friedberg JW

Clinical lymphoma, myeloma & leukemia.. 2016 June 16 (6):322-328.e2. Epub 04/02/2016.

Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma.

Reagan PM, Friedberg JW

Current treatment options in oncology.. 2015 July 16 (7):32. Epub 1900 01 01.

Brentuximab vedotin for the treatment of Hodgkin's and non-Hodgkin's lymphoma.

Reagan, P.M. and J.W. Friedberg.

Expert Opinion on Orphan Drugs. 2015; 3(5): p. 609-618.

Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma.

Reagan PM, Friedberg JW

Future oncology.. 2015 11 (10):1543-53. Epub 1900 01 01.

Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy.

Reagan P, Pani A, Rosner MH

American journal of kidney diseases : the official journal of the National Kidney Foundation.. 2014 January 63 (1):141-7. Epub 09/08/2013.

The snow-shoveler's ST elevation myocardial infarction.

Janardhanan R, Henry Z, Hur DJ, Lin CM, Lopez D, Reagan PM, Rudnick SR, Koshko TJ, Keeley EC

The American journal of cardiology.. 2010 August 15106 (4):596-600. Epub 1900 01 01.

Chemosensory responses to CO2 in multiple brain stem nuclei determined using a voltage-sensitive dye in brain slices from rats.

Erlichman JS, Boyer AC, Reagan P, Putnam RW, Ritucci NA, Leiter JC

Journal of neurophysiology.. 2009 September 102 (3):1577-90. Epub 06/24/2009.

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.

Ratings

During this visit, did this provider spend enough time with you?

5.0 stars

During this visit, did this provider show respect for what you had to say?

5.0 stars

During this visit did this provider give you easy to understand information about these health questions or concerns?

4.9 stars

During this visit, did this provider listen carefully to you?

5.0 stars

During this visit, did this provider explain things in a way that was easy to understand?

5.0 stars

Patient Comments

Good

Jul 26, 2024

5.0 stars

Dr. Reagan's deep professional knowledge, his caring and thoughtful approach to our meetings are making a profound impact on me. His thorough preparation for our appointments and his ability to communicate are critical for helping me make informed decisions. I leave our time together educated, uplifted and inspired.I am confident that he will lead and assist me through this challenging journey

Jul 07, 2024

5.0 stars

All experiences were excellent

Jun 29, 2024

5.0 stars

Dr. Reagan is a fantastic physician, I trust him with my life.

Jun 13, 2024

5.0 stars

Dr Reagan was very patient & understanding of all my questions. He spent a good deal of time explaining my options for further treatment.

Apr 20, 2024

5.0 stars

Dr. Reagan is a wonderful physician. I have great confidence in his knowledge and care. In my interactions with him I always feel that I am treated with respect, support and concern.

Mar 22, 2024

5.0 stars

Dr Reagan is extremely thorough & patient with my many questions. I feel he genuinely is concerned for my well being.

Mar 19, 2024

5.0 stars

Dr. Reagan is " as good as it gets " in terms of trustworthy, smart, engaging, patience and kind ".

Mar 07, 2024

5.0 stars

Everything went really good. Looking forward to being while again.

Feb 17, 2024

5.0 stars

Dr. Reagan always listens carefully to my concerns and explains risks and benefits of whatever course of action he recommends.

Dec 16, 2023

5.0

Dr. Reagan is AWESOME in every way!!

Jul 13, 2023

5.0

Dr. Reagan demonstrates a compassionate & educated concern for me. He readily shares his knowledge and effectively communicates understanding of all my medical concerns

Jun 10, 2023

5.0

Dr. Reagan has always listened to any questions or comments that I had and thoroughly explained my treatment and options.

May 24, 2023

5.0

As always, Dr. Reagan is the best.

May 22, 2023

5.0

Wonderful staff and Dr.

May 18, 2023

5.0

He is very professional and personable as well.

May 12, 2023

5.0

Very good overall. Listened, took the time to explain all so that it was understandable. Respected patient's concerns and preferences.

Apr 24, 2023

5.0

Dr. Reagan is amazing. [...]

Feb 27, 2023

5.0

Good

Jan 01, 2023

5.0

Dr. Reagan has been a very caring, informative oncologist.

Dec 14, 2022

5.0

Treated very good

Dec 09, 2022

5.0

I'm very comfortable and confident with Dr Reagan. He and his team are absolutely fantastic!

Dec 07, 2022

5.0

Dr. Reagan is the best...

Nov 21, 2022

5.0

The doctor spelled out my condition of future treatments.

Oct 28, 2022

5.0

I think Dr Reagan is so amazing. He takes his time with you and explains things so well. He is wonderful.

Oct 28, 2022

5.0

Dr. Reagan was & is caring from the 1st visit. He showed empathy and reassurance and helped us feel hopeful & confident. He helped us take a frightening situation & turn it into something we could handle he is the best dr. we could ask for.

Sep 22, 2022

5.0

Dr Reagan is just amazing. He absolutely knows his stuff. He lets you know everything and puts your mind at ease. That is so important when dealing with cancer.

Sep 15, 2022

5.0

Excellent care from the Dr. Always takes the time to listen and discuss my care. Very appreciative of being made important enough to spend the time with me (and my wife).

Aug 15, 2022

5.0

Overall visit was satisfactory.

Jul 24, 2022

5.0

Dr. Reagan " has it all " in terms of personality, knowledge of his trade, and belief that the action plan he recommends is the best one. He builds trust quickly by presenting the facts about the health issue at hand and best correction action plan to solve the problem. He comes across as a sincere, regular guy with credibility. His style and natural/relaxed way of dealing with the patient is special as it puts the patient at ease to ask any question and react as they feel fit. To say he is a " gem " is an understatement. Many doctors are not this way. Some are too stiff, too serious, make patients feel they should just listen and obey following the cook book for action ! Getting Dr. Reagan as my Oncologist is a very good thing. Thank you good doctor !

May 26, 2022

5.0

Dr. Reagan is so important for me... He saved my life. Always the best!!!

May 20, 2022

5.0

Good.

May 18, 2022

5.0

Dr. Reagan and his NP are amazing. I feel I am in such good hands.

Mar 25, 2022

Dr. Reagan is an excellent doctor!

Mar 23, 2022

5.0

Dr Reagan is a good listener. He is eager to share his knowledge in a professional manner. He is very authentic and sincere

Mar 18, 2022

5.0

I was treatedery good. [...]

Mar 10, 2022

Both Sheri and Pat Reagan are great. Helpful and very knowledgeable.

Feb 04, 2022